Compare Natera Inc. Common Stock (NTRA) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs PAGSEG Inc — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while PAGSEG Inc trades at $10.83 (market cap $2.99B). The key difference: Natera Inc. Common Stock is far larger — about 19.1× PAGSEG Inc's market cap, and PAGSEG Inc pays a 10.34% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and PAGSEG Inc for 27 Days on average.
| NTRA | PAGS | |
|---|---|---|
Market Cap | $57.03B | $2.99B |
Volume | 1,131,157 | 3,873,797 |
Sector | Health | Industrials |
52-Week High | $425.64 | $12.00 |
52-Week Low | $179.42 | $8.44 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $56.18B | $11.05B |
Dividend Yield | — | 10.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
PAGS trades at $10.99, down 1.35% on the day, with a bullish technical signal from moving averages but overbought short-term RSI readings. The company reported a Q2 2026 EPS beat of $0.41 vs. $0.389 expected, with revenue growth to $20.6B in 2026 and a net income margin of 10.45%. A dividend of $0.28 is scheduled for payment on September 30, 2026.
The stock presents a value opportunity with low P/E (7.31) and P/S (0.76) ratios, supported by strong analyst consensus (62.5% buy ratings) and a $10.70 price target. Key risks include macroeconomic pressures in Brazil and elevated credit losses, but robust cash flow and banking growth underpin long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
